Evidence map›Paper›PMID 30154714›Full record

ArticleFrontiers in pharmacology2018

A Nanomicellar Prodrug Carrier Based on Ibuprofen-Conjugated Polymer for Co-delivery of Doxorubicin.

Zuojun Li, Jingjing Sun, Yixian Huang, Yanhua Liu, Jieni Xu, Yichao Chen, Lei Liang, Jiang Li, Qiongfeng Liao, Song Li and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Engineering Nanoscale Drug Delivery Systems for Pain.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Zuojun LiDepartment of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, China.
Jingjing SunCenter for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, United States.
Yixian HuangCenter for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, United States.
Yanhua LiuDepartment of Pharmaceutics, School of Pharmacy, Ningxia Medical University, Yinchuan, China.
Jieni XuCenter for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, United States.
Yichao ChenCenter for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, United States.
Lei LiangGuangdong Second Provincial General Hospital, Guangzhou, China.
Jiang LiCenter for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, United States.
Qiongfeng LiaoSchool of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.
Song LiCenter for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, United States.
Kechao ZhouState Key Laboratory of Powder Metallurgy, Department of Pharmaceutical Sciences, School of Pharmacy, Central South University, Changsha, China.
University of Pittsburgh · USState Key Laboratory of Powder MetallurgyGuangdong Provincial People's Hospital · CNGuangzhou University of Chinese Medicine · CNNingxia Medical University · CN

Funding

Immunostimulatory Nanocarrier for Breast Cancer ImmunochemotherapyR01CA219399 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LI, SONG · 2017 to 2021
$2.3M
Nanotherapeutics for Synergistic Targeting of Myc in Prostate CancerR01CA223788 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LI, SONG · 2018 to 2022
$1.8M
Targeted Combination Therapy for Breast CancerR01CA174305 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LI, SONG · 2014 to 2018
$1.6M
NCI NIH HHS R01 CA174305NCI NIH HHS R01 CA219399NCI NIH HHS R01 CA223788
6 · The paper itself

Abstract

Ibuprofen (IBU) is a non-steroidal anti-inflammatory drug (NSAID), which is widely used to reduce fever and treat inflammation and acute pain. Recently, its application in cancer treatment is also being explored. In this work, we synthesized a well-defined IBU-based amphiphilic diblock copolymer via reversible addition fragmentation transfer (RAFT) polymerization of IBU-based vinyl monomer. The amphiphilic copolymer POEG-

Indexed as

carrierco-deliverydoxorubicinibuprofennanomicellarprodrug

Identifiers

PMID30154714
PMCPMC6102750
OpenAlexW2810717675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.